Aptevo Therapeutics Inc
APVOAptevo Therapeutics Inc. is a biotechnology company focused on developing innovative immuno-oncology and hematology therapies. The company specializes in leveraging its proprietary ADAPTIR® bispecific antibody platform to create treatments aimed at improving outcomes for patients with cancer and blood disorders. Founded with a focus on immunotherapy, Aptevo integrates advanced scientific research with clinical development to address unmet medical needs.
Company News
Aptevo Therapeutics reported a net loss of $8.40 per share in Q2 2025, significantly better than analyst estimates. The company's lead bispecific antibody, mipletamig, showed promising 85% remission rates in acute myeloid leukemia trials, and raised $15.9 million in equity to extend its cash runway.
Bloom Energy shares jumped 12.1% after announcing a strategic partnership with CoreWeave to deploy its fuel cells for on-site power generation at a data center. Several other stocks also saw significant pre-market movements, both positive and negative.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).
